Cargando…

Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study

BACKGROUND AND PURPOSE: We studied whether anticoagulant use and outcomes differed between rural versus urban Canadian non-valvular atrial fibrillation (NVAF) patients prior to the introduction of direct oral anticoagulant drugs. METHODS: Retrospective cohort study of 25,284 adult Albertans with NVA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Cynthia, McMurtry, Michael Sean, Sandhu, Roopinder K., Youngson, Erik, Ezekowitz, Justin A., Kaul, Padma, McAlister, Finlay A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605516/ https://www.ncbi.nlm.nih.gov/pubmed/26466118 http://dx.doi.org/10.1371/journal.pone.0140607

Ejemplares similares

Trends in Uptake and Adherence to Oral Anticoagulation for Patients With Incident Atrial Fibrillation at High Stroke Risk Across Health Care Settings
por: Yogasundaram, Haran, et al.
Publicado: (2022)

Patients With Heart Failure Readmitted to the Original Hospital Have Better Outcomes Than Those Readmitted Elsewhere
por: McAlister, Finlay A., et al.
Publicado: (2017)

Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users
por: Kaul, Padma, et al.
Publicado: (2021)

Nationwide Study of Sex Differences in Incident Heart Failure in Newly Diagnosed Nonvalvular Atrial Fibrillation
por: Yogasundaram, Haran, et al.
Publicado: (2022)

Defining and validating comorbidities and procedures in ICD-10 health data in ST-elevation myocardial infarction patients
por: Youngson, Erik, et al.
Publicado: (2016)

Total and Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease Registry
por: Tran, Dat T., et al.
Publicado: (2019)

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
por: McAlister, Finlay A., et al.
Publicado: (2020)

Towards artificial intelligence-based learning health system for population-level mortality prediction using electrocardiograms
por: Sun, Weijie, et al.
Publicado: (2023)

Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010–2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network
por: McAlister, Finlay A., et al.
Publicado: (2018)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Variation in Critical Care Unit Admission Rates and Outcomes for Patients With Acute Coronary Syndromes or Heart Failure Among High‐ and Low‐Volume Cardiac Hospitals
por: van Diepen, Sean, et al.
Publicado: (2015)

Cost‐Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation
por: Lau, Darren, et al.
Publicado: (2021)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

External Validation and Refinement of Emergency Heart Failure Mortality Risk Grade Risk Model in Patients With Heart Failure in the Emergency Department
por: Sepehrvand, Nariman, et al.
Publicado: (2019)

Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: A retrospective cohort study
por: McAlister, Finlay A., et al.
Publicado: (2016)

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation
por: Pengo, Vittorio, et al.
Publicado: (2015)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

A Population-Based Study of Unexplained/Lone Atrial Fibrillation: Temporal Trends, Management, and Outcomes
por: Roston, Thomas M., et al.
Publicado: (2021)

An Update on the Development and Feasibility Assessment of Canadian Quality Indicators for Atrial Fibrillation and Atrial Flutter
por: Sandhu, Roopinder K., et al.
Publicado: (2019)

Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study
por: Selby, Rita, et al.
Publicado: (2023)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study)
por: Dalmau Llorca, M. Rosa, et al.
Publicado: (2021)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

The COVID-19 pandemic did not negatively impact frequency or continuity of outpatient care in Alberta, Canada
por: McAlister, Finlay A., et al.
Publicado: (2023)

Detecting Patients With Nonvalvular Atrial Fibrillation and Atrial Flutter in the Canadian Primary Care Sentinel Surveillance Network: First Steps
por: Queenan, John A., et al.
Publicado: (2020)

Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
por: Bo, Simona, et al.
Publicado: (2007)

How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?
por: Kim, Jun Hyung, et al.
Publicado: (2009)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial
por: Yu, Yi-bo, et al.
Publicado: (2018)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
por: Luengsupabul, Sirote, et al.
Publicado: (2020)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
por: Welander, Frida, et al.
Publicado: (2022)

Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada
por: McAlister, Finlay A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n5tdluj935l0t8gdgp1qv6cisp